Sanctuary Advisors LLC Purchases 55,636 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Sanctuary Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 94% during Q4, buying an additional 55,636 shares to hold 114,797 shares worth about $2.68 million.
• Analysts have recently upgraded the stock—three "Strong Buy" and three "Buy" ratings—leaving an average consensus of "Strong Buy" and an average price target of $34.00.
• Institutional investors own approximately 79.22% of CPRX, which recently traded near $28.74 with a market cap of about $3.51 billion and a PE ratio of 17.01.

Sanctuary Advisors LLC grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 94.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 114,797 shares of the biopharmaceutical company's stock after purchasing an additional 55,636 shares during the period. Sanctuary Advisors LLC owned approximately 0.09% of Catalyst Pharmaceuticals worth $2,679,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Jones Financial Companies Lllp increased its position in shares of Catalyst Pharmaceuticals by 14.0% in the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company's stock valued at $79,000 after acquiring an additional 498 shares during the last quarter. Navellier & Associates Inc. increased its position in shares of Catalyst Pharmaceuticals by 6.6% in the third quarter. Navellier & Associates Inc. now owns 13,346 shares of the biopharmaceutical company's stock valued at $263,000 after acquiring an additional 822 shares during the last quarter. E Fund Management Co. Ltd. increased its position in shares of Catalyst Pharmaceuticals by 8.9% in the second quarter. E Fund Management Co. Ltd. now owns 10,656 shares of the biopharmaceutical company's stock valued at $231,000 after acquiring an additional 871 shares during the last quarter. Juncture Wealth Strategies LLC increased its position in shares of Catalyst Pharmaceuticals by 1.1% in the fourth quarter. Juncture Wealth Strategies LLC now owns 84,342 shares of the biopharmaceutical company's stock valued at $1,969,000 after acquiring an additional 940 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Catalyst Pharmaceuticals by 1.0% in the second quarter. California State Teachers Retirement System now owns 99,257 shares of the biopharmaceutical company's stock valued at $2,154,000 after acquiring an additional 992 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on CPRX shares. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Citigroup lifted their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a "buy" rating in a research report on Tuesday, March 3rd. Truist Financial raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, March 25th. Zacks Research raised Catalyst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 3rd. Finally, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Friday, March 27th. Three research analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the company's stock. According to MarketBeat.com, Catalyst Pharmaceuticals has an average rating of "Strong Buy" and an average price target of $34.00.

Catalyst Pharmaceuticals Stock Up 2.2%

Shares of NASDAQ CPRX opened at $28.74 on Friday. The business's 50 day moving average price is $24.91 and its two-hundred day moving average price is $23.67. The company has a market cap of $3.51 billion, a PE ratio of 17.01, a price-to-earnings-growth ratio of 0.91 and a beta of 0.67. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company's mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company's lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.